Advances in Nephrology and Dialysis. Proceedings of the 29th 'San Carlo' Course, Milan, Italy, 7-10 December 1997: Advanced glycation end-products in diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 14, Issue SUPPL. 3, 1999, Pages 1-9

  Friedman, E A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; GLUCOSE;

CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; GLYCATION; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RODENT; SYSTEMIC DISEASE; UREMIA;

EID: 0033049779     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (82)

1. Mauer SM, Chavers BM. A comparison of kidney disease in type I and type II diabetes. Adv Exp Med Biol 1985; 189: 299-303
2. U.S. Renal Data System, USRDS 1997 Annual Data Report, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD: April 1997
3. Friedman EA. Diabetic nephropathy is a hyperglycemic glomerulopathy. Arch Intern Med 1981; 142: 1269-1270
4. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-1720
5. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 1626-1632
6. Wu M-S, Yu C-C, Yang C-W et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997; 12: 2105-2110
7. Porte D Jr, Schwartz MW. Diabetes complications: why is glucose potentially toxic? Science 1996; 272: 699-670
8. Craven PA, Studer RK, Negrete H, DeRubertis FR. Protein kinase C in diabetic nephropathy. J Diabetes Complications 1995; 9: 241-245
9. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform bII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility of glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-11063
10. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995; 38: 387-394
11. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology - from West to the rest. Diabetes Care 1992; 15: 232-252
12. Harris M, Hadden WC, Knowles WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987; 36: 523-534
13. Stephens GW, Gillaspy JA, Clyne D, Mejia A, Pollak VE. Racial differences in the incidence of end-stage renal disease in Types I and II diabetes mellitus. Am J Kidney Dis 1990; 15: 562-567
14. Haffner SM, Hazuda HP, Stern MP, Patterson JK, Van-Heuven WA, Fong D. Effects of socioeconomic status on hyperglycemia and retinopathy levels in Mexican Americans with NIDDM. Diabetes Care 1989; 12: 128-134
15. National Diabetes Data Group. Diabetes in America. NIH Publication No. 85-1468, August 1985
16. Council on Ethical and Judicial Affairs. Black-white disparities in health care. J Am Med Assoc 1990; 163: 2344-2346
17. Mauer SM, Chavers BM. A comparison of kidney disease in type I and type II diabetes. Adv Exp Med Biol 1985; 189: 299-303
18. Melton LJ, Palumbo PJ, Chu CP. Incidence of diabetes mellitus by clinical type. Diabetes Care 1983; 6: 75-86
19. Abourizk NN, Dunn JC. Types of diabetes according to National Diabetes Data Group Classification. Limited applicability and need to revisit. Diabetes Care 1990; 13: 1120-1122
20. Sims EAH, Calles-Escandon J. Classification of diabetes. A fresh look for the 1990s? Diabetes Care 1990; 13: 1123-1127
21. Ritz E, Stefanski A. Diabetic nephropathy in Type II diabetes. Am J Kidney Dis 1996; 202: 167-194
22. Biesenback G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994; 9: 1097-1102
23. Sheehy MJ. HLA and insulin-dependent diabetes. A protective perspective. Diabetes 1992; 41: 123-129
24. Wirta O, Pasternack A, Laippala P, Turjanmaa V. Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol 1996; 45: 10-17
25. Mailloux LU, Bellucci AG, Napolitano B, Mossey RT, Wilkes BM, Bluestone PA. Death by withdrawal from dialysis: a 20-year clinical experience. J Am Soc Nephrol 1993; 3: 1031-1037
26. Berman DH, Friedman EA, Lundin AP. Aggressive ophthalmological management in diabetic ESRD: a study of 31 consecutively referred patients. Am J Nephrol 1992; 12: 344-350
27. Escalente DA, Kim DK, Garber AJ. Atherosclerotic cardiovascular disease. In: DeFronzo RA, ed. Current Therapy of Diabetes Mellitus. Mosby, St. Louis: 1998: 176-192
28. Harkles L, Boulton AJM. The diabetic foot. In: DeFronzo RA, ed. Current Therapy of Diabetes Mellitus. Mosby, St. Louis: 1998: 195-200
29. Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 1997; 46 [Suppl 2]: S67-S76
30. Battle WM, Cohen JD, Snape WJ Jr. Disorders of colonic motility in patients with diabetes mellitus. Yale J Biol Med 1983; 56: 277-283
31. Gavin LA, Lyons L, Kitzmiller JL. Type I diabetes mellitus in pregnancy. In: DeFronzo RA, ed. Current Therapy of Diabetes Mellitus. Mosby, St. Louis: 1998: 228-236
32. Miodovnik M, Rosenn BM, Khoury JC, Grigsby JL, Siddiqi TA. Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Gynecol 1996; 174: 1180-1191
33. Kaaja R, Sjoberg L, Hellsted T, Immonenen I, Sane T, Teramo K. Long-term effects of pregnancy on diabetic complications. Diabetes Med 1996; 13: 165-169
34. Pommer W, Bressel F, Chen F, Molzahn. There is room for improvement of preterminal care in diabetic patients with end-stage renal failure - the epidemiological evidence in Germany. Nephrol Dial Transplant 1997; 12: 1318-1230
35. Passa P. Diabetic nephropathy in the NIDDM patient on the interface between diabetology and nephrology. What do we have to improve? Nephrol Dial Transplant 1997; 12: 1316-1317
36. Catalano C, Goodship TH, Granham KA et al. Withdrawal of renal replacement therapy in Newcastle upon Tyne: 1964-1993. Nephrol Dial Transplant 1996; 11: 133-139
37. Ifudu O, Mayers J, Matthew J, Tan CC, Cambridge A, Friedman EA. Dismal rehabilitation in geriatric inner-city hemodialysis patients. J Am Med Assoc 1994; 271: 29-33
38. Lowder GM, Perri NA, Friedman EA. Demographics, diabetes type, and degree of rehabilitation in diabetic patients on maintenance hemodialysis in Brooklyn. J Diabetic Complications 1988; 2: 218-226
39. Legrain M, Rottembourg J, Bentchikou A et al. Dialysis treatment of insulin dependent diabetic patients. Ten years experience. Clin Nephrol 1984; 21: 72-81
40. Rubin J, Hsu H. Continuous ambulatory peritoneal dialysis: ten years at one facility. Am J Kidney Dis 1991; 17: 165-169
41. Churchill DNMN, Thorpe KE, Vonesh EF, Keshaviah PR. Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) peritoneal dialysis study group. J Am Soc Nephrol 1997; 8: 965-971
42. Habach G, Bloembergen WE, Mauger EA, Wolfe RA, Port FK. Hospitalization among United States dialysis patients: hemodialysis versus peritoneal dialysis. J Am Soc Nephrol 1995; 11: 1940-1948
43. Fenton SS, Schaubel DE, Desmeules M et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30: 334-342
44. Shaffer D, Simpson MA, Madras PN et al. Kidney transplantation in diabetic patients using cyclosporine. Five-year follow-up. Arch Surg 1995; 130: 287-288
45. Diagnostic and therapeutic technology assessment (DATTA). Pancreatic transplantations. J Am Med Assoc 1991; 265: 510-514
46. Sutherland D, Gruessner A, Moudry-Munns K. International Pancreas Transplant Registry report. Transplant Proc 1994; 26: 407-411
47. Ramsay RC, Goetz FC, Sutherland DE et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 208-214
48. Remuzzi G, Ruggenenti P, Mauer SM. Pancreas and kidney/pancreas transplants: experimental medicine or real improvement? Lancet 1994; 353: 27-31
49. Taylor RJ, Bynon JS, Stratta RJ. Kidney/pancreas transplantation: a review of the current status. Urol Clin North Am 1994; 21: 343-354
50. Mallick NP, Jones E, Selwood N. The European (European Dialysis and Transplantation Association-European Renal Association) Registry. Am J Kidney Dis 1995; 25: 176-187
51. Locatelli F, Marcelli D, Conte F. Dialysis patient outcomes in Europe vs the USA. Why do Europeans live longer? Nephrol Dialysis Transplant 1997; 12: 1816-1819
52. Gokal R, Jakubowski C, King J et al. Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-year analysis of a prospective multicentre study. Lancet 1987; 2: 1105-1109
53. Friedman EA. Death on Hemodialysis: Preventable or Inevitable? Kluwer Academic Publishers, Dordrecht: 1994
54. Friedman EA. ESRD therapy: an American success story. J Am Med Assoc 1996; 275: 1118-1122
55. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer, in: MacLeod CM, ed., Evaluation of Chemotherapeutic Agents. Columbia University Press, New York: 1949: 191-205
56. Carlson DM, Johnson WJ, Kjellstrand CM. Functional status of patients with end-stage renal disease. Mayo Clin Proc 1987; 62: 338-344
57. Gutman RA, Stead WW, Robinson RR. Physical activity and employment status of patients on maintenance dialysis. N Engl J Med 1981; 304: 309-313
58. Ifudu O, Paul H, Mayers JD, et al. Pervasive failed rehabilitation in center-based maintenance hemodialysis patients. Am J Kidney Dis 1994; 23: 394-400
59. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
60. Koschinsky T, He CJ, Mitsuhashi T et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-6479
61. Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995; 96: 1395-1403
62. Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619-628
63. Vlassara H. Serum advanced glycosylation end products: a new class of uremic toxins? Blood Purif 1994; 12: 54-59
64. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46: 661-665
65. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46: 216-222
66. Imai N, Nishi S, Suzuki Y et al. Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy. Nephron 1997; 76: 153-160
67. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. New Engl J Med 1991; 325: 836-842
68. Bucala R, Makita Z, Vega G et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-9445
69. Way KJ, Reid JJ. Effect of aminoguanidine on the impaired nitric oxide-mediated neurotransmission in anococcygeus muscle from diabetic rats. Neurapharmacology 1994; 33: 1315-1322
70. Knowx LK, Stewart AG, Hayward PG, Morrison WA. Nitric oxide synthase inhibitors improve skin flap survival in the rat. Microsurgery 1994; 15: 708-711
71. Tilton RG, Chang K, Corbett JA et al. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 1994; 35: 3278-3288
72. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90: 1110-1115
73. Wong GKT, Marsden PA. Nitric oxide synthases: regulation in disease. Nephrol Dial Transplant 1996; 11: 215-220
74. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-29
75. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632
76. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-29
77. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-35
78. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93: 1905-1912
79. Archibald V, Cotter MA, Keegan A, Cameron NE. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn-Schmiedbergs Arch Pharmacol 1996; 353: 584-591
80. Brownlee M. Pharmacological modulation of the advanced glycosylation reaction. Prog Clin Biol Res 1989; 304: 235-248
81. Nicholls K, Mandel TE. Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. Lab Invest 1989; 60: 486-491
82. Lyons TJ, Dailie KE, Dyer DG, Dunn JA, Baynes JW. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87: 1910-1915